Top Markets
Coin of the day
Novan, Inc. Novan, Inc.

Novan, Inc.

NOVN
株式のランク #39525
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
株価
$0.056
最終同期: 2023-08-21
時価総額
$451.38K
変化(1日)
8.74%
変化(1年)
0.00%
US
取引 Novan, Inc. (NOVN)

カテゴリー

Novan, Inc.(NOVN)の配当利回りの履歴
Novan, Inc.(銘柄コード: NOVN)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Novan, Inc.(NOVN)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)